Lactogens and estrogens in breast cancer chemoresistance

References

• Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat. Rev.34, 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med.354, 270–282 (2006).
   PubMed Web of Science ®Google Scholar
• Clevenger CV, Gadd SL, Zheng J. New mechanisms for PRLr action in breast cancer. Trends Endocrinol. Metab.20, 223–229 (2009).
   PubMed Web of Science ®Google Scholar
• Lapensee EW, Ben-Jonathan N. Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. Endocr. Relat. Cancer17, R91–R107 (2010).
   Google Scholar
• Carver KC, Arendt LM, Schuler LA. Complex prolactin crosstalk in breast cancer: new therapeutic implications. Mol. Cell Endocrinol.307, 1–7 (2009).
   PubMedGoogle Scholar
• Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor α mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res.67, 5337–5344 (2007).
   PubMedGoogle Scholar
• Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr. Rev.17, 639–669 (1996).
   PubMed Web of Science ®Google Scholar
• Kimura AP, Sizova D, Handwerger S, Cooke NE, Liebhaber SA. Epigenetic activation of the human growth hormone gene cluster during placental cytotrophoblast differentiation. Mol. Cell Biol.27, 6555–6568 (2007).
   PubMedGoogle Scholar
• Harvey S. Extrapituitary growth hormone. Endocrine38, 335–359 (2010).
   PubMedGoogle Scholar
• Keeler C, Dannies PS, Hodsdon ME. The tertiary structure and backbone dynamics of human prolactin. J. Mol. Biol.328, 1105–1121 (2003).
   PubMed Web of Science ®Google Scholar
• Ben-Jonathan N, Lapensee CR, Lapensee EW. What can we learn from rodents about prolactin in humans? Endocr. Rev.29, 1–41 (2008).
   PubMed Web of Science ®Google Scholar
• Xu J, Zhang Y, Berry PA et al. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Mol. Endocrinol.25(4), 597–610 (2011).
   PubMedGoogle Scholar
• Bernichtein S, Touraine P, Goffin V. New concepts in prolactin biology. J. Endocrinol.206, 1–11 (2010).
   PubMed Web of Science ®Google Scholar
• Zinger M, McFarland M, Ben-Jonathan N. Prolactin expression and secretion by human breast glandular and adipose tissue explants. J. Clin. Endocrinol. Metab.88, 689–696 (2003).
   PubMed Web of Science ®Google Scholar
• Ben-Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol. Metab.13, 245–250 (2002).
   PubMed Web of Science ®Google Scholar
• Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res. Treat.111, 241–250 (2008).
   PubMed Web of Science ®Google Scholar
• Howell SJ, Anderson E, Hunter T, Farnie G, Clarke RB. Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res.10, R68 (2008).
   PubMed Web of Science ®Google Scholar
• Perry JK, Mohankumar KM, Emerald BS, Mertani HC, Lobie PE. The contribution of growth hormone to mammary neoplasia. J. Mammary Gland Biol. Neoplasia13, 131–145 (2008).
   PubMedGoogle Scholar
• Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr. Rev.30, 51–74 (2009).
   PubMed Web of Science ®Google Scholar
• Perry JK, Emerald BS, Mertani HC, Lobie PE. The oncogenic potential of growth hormone. Growth Horm. IGF Res.16, 277–289 (2006).
   PubMed Web of Science ®Google Scholar
• Mojarrad M, Momeny M, Mansuri F et al. Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen. Med. Oncol.27, 474–480 (2010).
   PubMedGoogle Scholar
• Chhabra Y, Waters MJ, Brooks AJ. Role of the growth hormone-IGF-1 axis in cancer. Exp. Rev. Endocrinol. Metab.6, 71–84 (2011).
   PubMedGoogle Scholar
• Raccurt M, Lobie PE, Moudilou E et al. High stromal and epithelial human GH gene expression is associated with proliferative disorders of the mammary gland. J. Endocrinol.175, 307–318 (2002).
   PubMed Web of Science ®Google Scholar
• Zatelli MC, Minoia M, Mole D et al. Growth hormone excess promotes breast cancer chemoresistance. J. Clin. Endocrinol. Metab.94, 3931–3938 (2009).
   PubMedGoogle Scholar
• Handwerger S. New insights into the regulation of human cytotrophoblast cell differentiation. Mol. Cell Endocrinol.323, 94–104 (2010).
   PubMedGoogle Scholar
• Horne CH, Reid IN, Milne GD. Prognostic significance of inappropriate production of pregnancy proteins by breast cancers. Lancet2, 279–282 (1976).
   PubMedGoogle Scholar
• Sheth NA, Suraiya JN, Sheth AR, Ranadive KJ, Jussawalla DJ. Ectopic production of human placental lactogen by human breast tumors. Cancer39, 1693–1699 (1977).
   PubMedGoogle Scholar
• Latham C, Zhang A, Nalbanti A et al. Frequent co-amplification of two different regions on 17q in aneuploid breast carcinomas. Cancer Genet. Cytogenet.127, 16–23 (2001).
   PubMedGoogle Scholar
• Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin. Chem.52, 345–351 (2006).
   PubMed Web of Science ®Google Scholar
• Butler SA, Iles RK. Ectopic human chorionic gonadotropin β secretion by epithelial tumors and human chorionic gonadotropin β-induced apoptosis in Kaposi’s sarcoma: is there a connection? Clin. Cancer Res.9, 4666–4673 (2003).
   PubMedGoogle Scholar
• Hu ZZ, Zhuang L, Dufau ML. Prolactin receptor gene diversity: structure and regulation. Trends Endocrinol. Metab.9, 94–102 (1998).
   PubMedGoogle Scholar
• Swaminathan G, Varghese B, Fuchs SY. Regulation of prolactin receptor levels and activity in breast cancer. J. Mammary Gland Biol. Neoplasia13, 81–91 (2008).
   PubMed Web of Science ®Google Scholar
• Ginsburg E, Alexander S, Lieber S et al. Characterization of ductal and lobular breast carcinomas using novel prolactin receptor isoform specific antibodies. BMC Cancer10, 678 (2010).
   PubMedGoogle Scholar
• Tran-Thanh D, Arneson NC, Pintilie M et al. Amplification of the prolactin receptor gene in mammary lobular neoplasia. Breast Cancer Res. Treat. DOI: 10.1007/s10549-010-1025-6 (2010) (Epub ahead of print).
   Google Scholar
• Teilum K, Hoch JC, Goffin V, Kinet S, Martial JA, Kragelund BB. Solution structure of human prolactin. J. Mol. Biol.351, 810–823 (2005).
   PubMedGoogle Scholar
• Jomain JB, Tallet E, Broutin I et al. Structural and thermodynamic bases for the design of pure prolactin receptor antagonists: x-ray structure of Del1-9-G129R-hPRL. J. Biol. Chem.282, 33118–33131 (2007).
   PubMedGoogle Scholar
• Voorhees JL, Brooks CL. Obligate ordered binding of human lactogenic cytokines. J. Biol. Chem.285, 20022–20030 (2010).
   PubMedGoogle Scholar
• Utama FE, Tran TH, Ryder A, LeBaron MJ, Parlow AF, Rui H. Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology150, 1782–1790 (2009).
   PubMed Web of Science ®Google Scholar
• Acosta JJ, Munoz RM, Gonzalez L et al. Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Mol. Endocrinol.17, 2268–2282 (2003).
   PubMedGoogle Scholar
• Piazza TM, Lu JC, Carver KC, Schuler LA. SRC family kinases accelerate prolactin receptor internalization, modulating trafficking and signaling in breast cancer cells. Mol. Endocrinol.23, 202–212 (2009).
   PubMedGoogle Scholar
• Fresno Vara JA, Carretero MV, Geronimo H, Ballmer-Hofer K, Martin-Perez J. Stimulation of c-Src by prolactin is independent of Jak2. Biochem. J.345(Pt 1), 17–24 (2000).
   PubMedGoogle Scholar
• Gutzman JH, Nikolai SE, Rugowski DE, Watters JJ, Schuler LA. Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos. Mol. Endocrinol.19, 1765–1778 (2005).
   PubMedGoogle Scholar
• Fox EM, Andrade J, Shupnik MA. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids74, 622–627 (2009).
   PubMed Web of Science ®Google Scholar
• Gonzalez L, Zambrano A, Lazaro-Trueba I et al. Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene28, 1298–1308 (2009).
   PubMed Web of Science ®Google Scholar
• Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N. Engl. J. Med.358, 2796–2803 (2008).
   PubMed Web of Science ®Google Scholar
• Ahmed S, Thomas G, Ghoussaini M et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat. Genet.41, 585–590 (2009).
   PubMed Web of Science ®Google Scholar
• Wheeler DA, Srinivasan M, Egholm M et al. The complete genome of an individual by massively parallel DNA sequencing. Nature452, 872–876 (2008).
   PubMed Web of Science ®Google Scholar
• Levy S, Sutton G, Ng PC et al. The diploid genome sequence of an individual human. PLoS Biol.5, e254 (2007).
   PubMed Web of Science ®Google Scholar
• Anghel A, Narita D, Seclaman E, Popovici E, Anghel M, Tamas L. Estrogen receptor α polymorphisms and the risk of malignancies. Pathol. Oncol. Res.16, 485–496 (2010).
   PubMed Web of Science ®Google Scholar
• Giess M, Lattrich C, Springwald A, Goerse R, Ortmann O, Treeck O. GPR30 gene polymorphisms are associated with progesterone receptor status and histopathological characteristics of breast cancer patients. J. Steroid Biochem. Mol. Biol.118, 7–12 (2010).
   PubMed Web of Science ®Google Scholar
• Canbay E, Degerli N, Gulluoglu BM, Kaya H, Sen M, Bardakci F. Could prolactin receptor gene polymorphism play a role in pathogenesis of breast carcinoma? Curr. Med. Res. Opin.20, 533–540 (2004).
   PubMed Web of Science ®Google Scholar
• Bogorad RL, Courtillot C, Mestayer C et al. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc. Natl Acad. Sci. USA105, 14533–14538 (2008).
   PubMed Web of Science ®Google Scholar
• Courtillot C, Chakhtoura Z, Bogorad R et al. Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas. J. Clin. Endocrinol. Metab.95, 271–279 (2010).
   PubMedGoogle Scholar
• Lee SA, Haiman CA, Burtt NP et al. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort. BMC Med. Genet.8, 72 (2007).
   PubMed Web of Science ®Google Scholar
• Vaclavicek A, Hemminki K, Bartram CR et al. Association of prolactin and its receptor gene regions with familial breast cancer. J. Clin. Endocrinol. Metab.91, 1513–1519 (2006).
   PubMed Web of Science ®Google Scholar
• Hinds DA, Stuve LL, Nilsen GB et al. Whole-genome patterns of common DNA variation in three human populations. Science307, 1072–1079 (2005).
   PubMed Web of Science ®Google Scholar
• Tworoger SS, Hankinson SE. Prolactin and breast cancer etiology: an epidemiologic perspective. J. Mammary Gland Biol. Neoplasia13, 41–53 (2008).
   PubMedGoogle Scholar
• Lissoni P, Vaghi M, Ardizzoia A et al. Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Neuro. Endocrinol. Lett.22, 27–29 (2001).
   PubMedGoogle Scholar
• Lissoni P, Bucovec R, Malugani F et al. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines. Anticancer Res.22, 1131–1134 (2002).
   PubMedGoogle Scholar
• Ramamoorthy P, Sticca R, Wagner TE, Chen WY. In vitro studies of a prolactin antagonist, hPRL-G129R n human breast cancer cells. Int. J. Oncol.18, 25–32 (2001).
   PubMed Web of Science ®Google Scholar
• Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br. J. Cancer91, 305–311 (2004).
   PubMed Web of Science ®Google Scholar
• Chakravarti P, Henry MK, Quelle FW. Prolactin and heregulin override DNA damage-induced growth arrest and promote phosphatidylinositol-3 kinase-dependent proliferation in breast cancer cells. Int. J. Oncol.26, 509–514 (2005).
   PubMedGoogle Scholar
• Lapensee EW, Schwemberger SJ, Lapensee CR, Bahassi EM, Afton SE, Ben-Jonathan N. Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase. Carcinogenesis30, 1298–1304 (2009).
   PubMed Web of Science ®Google Scholar
• Decatris MP, Sundar S, O’Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat. Rev.30, 53–81 (2004).
   PubMed Web of Science ®Google Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer7, 573–584 (2007).
   PubMed Web of Science ®Google Scholar
• Townsend DM, Findlay VL, Tew KD. Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol.401, 287–307 (2005).
   PubMed Web of Science ®Google Scholar
• Ambrosone CB, Sweeney C, Coles BF et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res.61, 7130–7135 (2001).
   PubMed Web of Science ®Google Scholar
• Peirce SK, Chen WY. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice. Oncogene23, 1248–1255 (2004).
   PubMed Web of Science ®Google Scholar
• Jongen VH, Hollema H, Van Der Zee AG, Heineman MJ. Aromatase in the context of breast and endometrial cancer. A review. Minerva Endocrinol.31, 47–60 (2006).
   PubMedGoogle Scholar
• Suzuki T, Miki Y, Nakamura Y et al. Sex steroid-producing enzymes in human breast cancer. Endocr. Relat. Cancer12, 701–720 (2005).
   PubMed Web of Science ®Google Scholar
• Pasqualini JR, Chetrite G, Blacker C et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab.81, 1460–1464 (1996).
   PubMed Web of Science ®Google Scholar
• Santen RJ, Santner SJ, Pauley RJ et al. Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J. Steroid Biochem. Mol. Biol.61, 267–271 (1997).
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Mouret-Reynier MA, Durando X et al. Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer. Expert Opin. Pharmacother.10, 1435–1447 (2009).
   PubMed Web of Science ®Google Scholar
• Gray J, Evans N, Taylor B, Rizzo J, Walker M. State of the evidence: the connection between breast cancer and the environment. Int. J. Occup. Environ. Health15, 43–78 (2009).
   PubMed Web of Science ®Google Scholar
• Wolff MS. Endocrine disruptors: challenges for environmental research in the 21st Century. Ann. NY Acad. Sci.1076, 228–238 (2006).
   PubMedGoogle Scholar
• Holloway AC, Anger DA, Crankshaw DJ, Wu M, Foster WG. Atrazine-induced changes in aromatase activity in estrogen sensitive target tissues. J. Appl. Toxicol.28, 260–270 (2008).
   PubMed Web of Science ®Google Scholar
• Falconer IR. Are endocrine disrupting compounds a health risk in drinking water? Int. J. Environ. Res. Public Health3, 180–184 (2006).
   PubMedGoogle Scholar
• Mense SM, Hei TK, Ganju RK, Bhat HK. Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environ. Health Perspect.116, 426–433 (2008).
   PubMed Web of Science ®Google Scholar
• Martin JH, Crotty S, Nelson PN. Phytoestrogens: perpetrators or protectors? Future Oncol.3, 307–318 (2007).
   PubMedGoogle Scholar
• Heldring N, Pike A, Andersson S et al. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev.87, 905–931 (2007).
   PubMed Web of Science ®Google Scholar
• Nilsson S, Makela S, Treuter E et al. Mechanisms of estrogen action. Physiol. Rev.81, 1535–1565 (2001).
   PubMed Web of Science ®Google Scholar
• Gertler A, Grosclaude J, Strasburger CJ, Nir S, Djiane J. Real-time kinetic measurements of the interactions between lactogenic hormones and prolactin-receptor extracellular domains from several species support the model of hormone-induced transient receptor dimerization. J. Biol. Chem.271, 24482–24491 (1996).
   PubMedGoogle Scholar
• Bai Z, Gust R. Breast cancer, estrogen receptor and ligands. Arch. Pharm.342, 133–149 (2009).
   PubMed Web of Science ®Google Scholar
• Van Den Bemd GJ, Kuiper GG, Pols HA, Van Leeuwen JP. Distinct effects on the conformation of estrogen receptor α and β by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. Biochem. Biophys. Res. Commun.261, 1–5 (1999).
   PubMed Web of Science ®Google Scholar
• Normanno N, Di MM, De ME et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer12, 721–747 (2005).
   PubMed Web of Science ®Google Scholar
• Khan SA, Bhandare D, Chatterton RT Jr. The local hormonal environment and related biomarkers in the normal breast. Endocr. Relat. Cancer12, 497–510 (2005).
   PubMed Web of Science ®Google Scholar
• Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol.19, 833–842 (2005).
   PubMed Web of Science ®Google Scholar
• Manavathi B, Kumar R. Steering estrogen signals from the plasma membrane to the nucleus: two sides of the coin. J. Cell Physiol.207, 594–604 (2006).
   PubMedGoogle Scholar
• Song RX, Fan P, Yue W, Chen Y, Santen RJ. Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer. Endocr. Relat. Cancer13(Suppl. 1), S3–S13 (2006).
   Google Scholar
• Watson CS, Bulayeva NN, Wozniak AL, Alyea RA. Xenoestrogens are potent activators of nongenomic estrogenic responses. Steroids72, 124–134 (2007).
   PubMed Web of Science ®Google Scholar
• Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu. Rev. Physiol.70, 165–190 (2008).
   PubMed Web of Science ®Google Scholar
• Filardo EJ, Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol. Metab.16, 362–367 (2005).
   PubMed Web of Science ®Google Scholar
• Filardo EJ, Graeber CT, Quinn JA et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin. Cancer Res.12, 6359–6366 (2006).
   PubMed Web of Science ®Google Scholar
• Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology146, 624–632 (2005).
   PubMed Web of Science ®Google Scholar
• Rodrik V, Zheng Y, Harrow F, Chen Y, Foster DA. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol. Cell Biol.25, 7917–7925 (2005).
   PubMedGoogle Scholar
• Huang Y, Ray S, Reed JC et al. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res. Treat.42, 73–81 (1997).
   PubMedGoogle Scholar
• Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res.55, 3902–3907 (1995).
   PubMed Web of Science ®Google Scholar
• Lagadec C, Adriaenssens E, Toillon RA et al. Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells. Oncogene27, 1472–1477 (2008).
   PubMed Web of Science ®Google Scholar
• Lapensee EW, Lapensee CR, Fox S, Schwemberger S, Afton S, Ben-Jonathan N. Bisphenol A and estradiol are equipotent in antagonizing cisplatin-induced cytotoxicity in breast cancer cells. Cancer Lett.290, 167–173 (2010).
   PubMed Web of Science ®Google Scholar
• Razandi M, Pedram A, Levin ER. Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol. Endocrinol.14, 1434–1447 (2000).
   PubMed Web of Science ®Google Scholar
• Zampieri L, Bianchi P, Ruff P, Arbuthnot P. Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells. Anticancer Res.22, 2253–2259 (2002).
   PubMed Web of Science ®Google Scholar
• Welshons WV, Nagel SC, vom Saal FS. Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. Endocrinology147, S56–S69 (2006).
   PubMed Web of Science ®Google Scholar
• Kang JH, Kondo F, Katayama Y. Human exposure to bisphenol A. Toxicology226, 79–89 (2006).
   PubMed Web of Science ®Google Scholar
• Le HH, Carlson EM, Chua JP, Belcher SM. Bisphenol A is released from polycarbonate drinking bottles and mimics the neurotoxic actions of estrogen in developing cerebellar neurons. Toxicol. Lett.176, 149–156 (2008).
   PubMed Web of Science ®Google Scholar
• Fernandez MF, Arrebola JP, Taoufiki J et al. Bisphenol-A and chlorinated derivatives in adipose tissue of women. Reprod. Toxicol.24, 259–264 (2007).
   PubMed Web of Science ®Google Scholar
• Yi B, Kim C, Yang M. Biological monitoring of bisphenol A with HLPC/FLD and LC/MS/MS assays. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.878, 2606–2610 (2010).
   PubMed Web of Science ®Google Scholar
• Vandenberg LN, Maffini MV, Sonnenschein C, Rubin BS, Soto AM. Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocr. Rev.30, 75–95 (2009).
   PubMed Web of Science ®Google Scholar
• Ben-Jonathan N, Hugo ER, Brandebourg TD. Effects of bisphenol A on adipokine release from human adipose tissue: implications for the metabolic syndrome. Mol. Cell Endocrinol.304, 49–54 (2009).
   PubMed Web of Science ®Google Scholar
• Singleton DW, Feng Y, Chen Y et al. Bisphenol-A and estradiol exert novel gene regulation in human MCF-7 derived breast cancer cells. Mol. Cell Endocrinol.221, 47–55 (2004).
   PubMed Web of Science ®Google Scholar
• Li X, Zhang S, Safe S. Activation of kinase pathways in MCF-7 cells by 17β-estradiol and structurally diverse estrogenic compounds. J. Steroid Biochem. Mol. Biol.98, 122–132 (2006).
   PubMedGoogle Scholar
• Walsh DE, Dockery P, Doolan CM. Estrogen receptor independent rapid non-genomic effects of environmental estrogens on [Ca2+]i in human breast cancer cells. Mol. Cell Endocrinol.230, 23–30 (2005).
   PubMed Web of Science ®Google Scholar
• Kuiper GG, Lemmen JG, Carlsson B et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology139, 4252–4263 (1998).
   PubMed Web of Science ®Google Scholar
• Watson CS, Bulayeva NN, Wozniak AL, Finnerty CC. Signaling from the membrane via membrane estrogen receptor-α: estrogens, xenoestrogens, and phytoestrogens. Steroids70, 364–371 (2005).
   PubMed Web of Science ®Google Scholar
• Hugo ER, Brandebourg TD, Woo JG, Loftus J, Alexander JW, Ben-Jonathan N. Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes. Environ. Health Perspect.116, 1642–1647 (2008).
   PubMed Web of Science ®Google Scholar
• Safe SH, Pallaroni L, Yoon K, Gaido K, Ross S, McDonnell D. Problems for risk assessment of endocrine-active estrogenic compounds. Environ. Health Perspect.110(Suppl. 6), 925–929 (2002).
   PubMed Web of Science ®Google Scholar
• Ariazi EA, Jordan VC. Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Curr. Top. Med. Chem.6, 203–215 (2006).
   PubMed Web of Science ®Google Scholar
• Okada H, Tokunaga T, Liu X, Takayanagi S, Matsushima A, Shimohigashi Y. Direct evidence revealing structural elements essential for the high binding ability of bisphenol A to human estrogen-related receptor-γ. Environ. Health Perspect.116, 32–38 (2008).
   PubMed Web of Science ®Google Scholar
• Ariazi EA, Clark GM, Mertz JE. Estrogen-related receptor α and estrogen-related receptor γ associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res.62, 6510–6518 (2002).
   PubMed Web of Science ®Google Scholar
• Lapensee EW, Tuttle TR, Fox SR, Ben-Jonathan N. Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-α-positive and -negative breast cancer cells. Environ. Health Perspect.117, 175–180 (2009).
   PubMed Web of Science ®Google Scholar
• Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr. Rev.26, 400–422 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobson EM, Hugo ER, Tuttle TR, Papoian R, Ben-Jonathan N. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Trends Endocrinol. Metab.21, 691–698 (2010).
   PubMed Web of Science ®Google Scholar